Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Other Non-Current Assets: 2021-2025

Historic Other Non-Current Assets for Summit Therapeutics (SMMT) over the last 4 years, with Sep 2025 value amounting to $7.0 million.

  • Summit Therapeutics' Other Non-Current Assets rose 277.56% to $7.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.0 million, marking a year-over-year increase of 277.56%. This contributed to the annual value of $2.5 million for FY2024, which is 41.05% down from last year.
  • Per Summit Therapeutics' latest filing, its Other Non-Current Assets stood at $7.0 million for Q3 2025, which was up 7.95% from $6.5 million recorded in Q2 2025.
  • Summit Therapeutics' Other Non-Current Assets' 5-year high stood at $7.0 million during Q3 2025, with a 5-year trough of $140,000 in Q3 2022.
  • Moreover, its 3-year median value for Other Non-Current Assets was $2.5 million (2024), whereas its average is $3.2 million.
  • In the last 5 years, Summit Therapeutics' Other Non-Current Assets surged by 2,994.29% in 2023 and then plummeted by 56.99% in 2024.
  • Summit Therapeutics' Other Non-Current Assets (Quarterly) stood at $170,000 in 2021, then surged by 239.41% to $577,000 in 2022, then surged by 649.05% to $4.3 million in 2023, then tumbled by 41.05% to $2.5 million in 2024, then skyrocketed by 277.56% to $7.0 million in 2025.
  • Its Other Non-Current Assets stands at $7.0 million for Q3 2025, versus $6.5 million for Q2 2025 and $4.1 million for Q1 2025.